Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perindopril.

D C O'Loughlin1, V L Chu, D Singh

  • 1Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University, Brooklyn, NY, USA.

Heart Disease (Hagerstown, Md.)
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tropical calcific pancreatitis.

The Ceylon medical journal·2008
Same author

Sudden decrease in bispectral index value during emergence from general anaesthesia.

Anaesthesia and intensive care·2008
Same author

Bilateral vocal cord palsy due to brain-stem cavernoma--a diagnostic dilemma!

Acta neurochirurgica·2008
Same author

Patient expectations for hallux valgus surgery.

Journal of orthopaedic surgery (Hong Kong)·2008
Same author

Dual elicitation for improved production of withaferin A by cell suspension cultures of Withania somnifera.

Applied biochemistry and biotechnology·2008
Same author

Visceral leishmaniasis in pregnancy - the role of amphotericin B.

Annals of tropical medicine and parasitology·2008
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Perindopril, a new angiotensin-converting enzyme inhibitor, effectively treats essential hypertension and congestive heart failure with once-daily dosing. It shows favorable tolerability and influences arterial wall properties.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Perindopril is a novel angiotensin-converting enzyme (ACE) inhibitor approved in the US.
  • It requires conversion to its active metabolite, perindoprilat.
  • Its extended duration of action permits once-daily dosing.

Purpose of the Study:

  • To review clinical trials on perindopril for essential hypertension, alone and in combination therapy.
  • To examine perindopril's efficacy in treating congestive heart failure.
  • To discuss perindopril's effects on arterial wall properties, tolerability, drug interactions, and dosage.

Main Methods:

  • Review of clinical trials involving perindopril in patients with essential hypertension.
  • Evaluation of studies assessing perindopril for congestive heart failure.

Related Experiment Videos

  • Analysis of data on perindopril's impact on arterial properties and safety profile.

    • Main Results:

    • Perindopril demonstrates efficacy in treating essential hypertension, both as monotherapy and in combination with other antihypertensives, particularly thiazide diuretics.
    • Clinical trials support the use of perindopril for managing congestive heart failure.
    • The drug influences arterial wall properties and exhibits acceptable tolerability with manageable drug interactions.

    Conclusions:

    • Perindopril is an effective ACE inhibitor for essential hypertension and congestive heart failure, offering the convenience of once-daily administration.
    • Its favorable pharmacokinetic profile and demonstrated clinical benefits support its role in cardiovascular therapy.
    • Further review of tolerability, interactions, and dosing confirms its clinical utility.